ArticleAging2020
Neuroprotective effects of p62(SQSTM1)-engineered lactic acid bacteria in Alzheimer's disease: a pre-clinical study.
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- A Systematic Review on the Effects of Different Types of Probiotics in Animal Alzheimer's Disease Studies.Frontiers in psychiatry · 2022Pooled it
- From lab to law: emerging applications, potential benefits, evolving regulatory framework and challenges for engineered probiotics.Microbial cell factories · 2026Review
- Mechanistic advances in exercise‑mediated regulation of autophagy dysfunction in Alzheimer's disease (Review).International journal of molecular medicine · 2026Review
- Icariin Against Neurodegeneration: A Focus in Cell Death Pathways.International journal of molecular sciences · 2026Review
- Targeting autophagy and programmed cell death in neurological diseases via probiotic intervention.Gut pathogens · 2025Review
- Exploring the Role of the Gut Microbiome Across the Lifespan: Implications for Aging and Metabolic Disorders.Journal of the Endocrine Society · 2025Review
- Linkage of circadian rhythm disruptions with Alzheimer's disease and therapeutic interventions.Acta pharmaceutica Sinica. B · 2025Review
- Metabolic engineering of Lactobacilli spp. for disease treatment.Microbial cell factories · 2025Review
- Harnessing the Power of Probiotics: Boosting Immunity and Safeguarding against Various Diseases and Infections.Recent advances in anti-infective drug discovery · 2025Review
- The Gut Microbiota Modulates Neuroinflammation in Alzheimer's Disease: Elucidating Crucial Factors and Mechanistic Underpinnings.CNS neuroscience & therapeutics · 2024Review
- Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators.Antibiotics (Basel, Switzerland) · 2024Review
- Microbiota-Gut-Brain Axis Dysregulation in Alzheimer's Disease: Multi-Pathway Effects and Therapeutic Potential.Aging and disease · 2024Review
- Damage to the Locus Coeruleus Alters the Expression of Key Proteins in Limbic Neurodegeneration.International journal of molecular sciences · 2024Article
- Potential for New Therapeutic Approaches by Targeting Lactate and pH Mediated Epigenetic Dysregulation in Major Mental Diseases.Biomedicines · 2024Review
- Recombinant probioticFrontiers in microbiology · 2024Article
- Gut microbiome-targeted therapies for Alzheimer's disease.Gut microbes · 2023Review
- Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives.Journal of diabetes and metabolic disorders · 2023Review
- Multiomic prediction of therapeutic targets for human diseases associated with protein phase separation.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Enhanced microglial dynamics and paucity of tau seeding in the amyloid plaque microenvironment contributes to cognitive resilience in Alzheimer's disease.bioRxiv : the preprint server for biology · 2023Article
- Evaluation of the Oral Bacterial Genome and Metabolites in Patients with Wolfram Syndrome.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegeneration characterized by neuron death ending in memory and cognitive decline. A major concern in AD research is the identification of new therapeutics that could prevent or delay the onset of the disorder, with current treatments being effective only in reducing symptoms. In this perspective, the use of engineered probiotics as therapeutic tools for the delivery of molecules to eukaryotic cells is finding application in several disorders. This work introduces a new strategy for AD treatment based on the use of a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.